TRIB VS PHGE Stock Comparison

PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatility
PerformanceAnalyst Price TargetsSentimentTechnicalsEarningsProfitVolatility

Performance

TRIB
10/100

TRIB returned -60.18% in the last 12 months. Based on SPY's performance of -21.29%, its performance is below average giving it a score of 10 of 100.

PHGE
100/100

PHGE returned 40.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

TRIB
83/100

3 analysts offer 12-month price targets for TRIB. Together, they have an average target of 0, the most optimistic target put TRIB at 0 within 12-months and the most pessimistic has TRIB at 0.

PHGE

"Analyst Price Targets" not found for PHGE

Sentiment

TRIB
67/100

TRIB had a bullish sentiment score of 67.18% across Twitter and StockTwits over the last 12 months. It had an average of 5.22 posts, 3.44 comments, and 2.83 likes per day.

PHGE

"Sentiment" not found for PHGE

Technicals

TRIB
11/100

TRIB receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

PHGE
82/100

PHGE receives a 82 of 100 based on 14 indicators. 11 are bullish, 2 are bearish.

Earnings

TRIB
10/100

TRIB has missed earnings 10 times in the last 20 quarters.

PHGE
100/100

PHGE has missed earnings 1 times in the last 20 quarters.

Profit

TRIB
48/100

Out of the last 20 quarters, TRIB has had 14 profitable quarters and has increased their profits year over year on 4 of them.

PHGE
10/100

Out of the last 20 quarters, PHGE has had 3 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

TRIB
50/100

TRIB has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

PHGE
44/100

PHGE has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Trinity Biotech plc Summary

Nasdaq / TRIB
Healthcare
Medical - Diagnostics & Research
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

BiomX Inc. Summary

Healthcare
Biotechnology
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.